Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Metformin is the most-prescribed oral medication to lower blood glucose worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in reducing risk of cardiovascular disease, the most costly complication of type 2 diabetes. We aimed to systematically identify and pool randomised trials reporting cardiovascular outcomes in which the effect of metformin was 'isolated' through comparison to diet, lifestyle or placebo. METHODS: We performed an electronic literature search of MEDLINE, EMBASE and the Cochrane Library. We also manually screened the reference lists of previous meta-analyses of trials of metformin identified through a MEDLINE search. We included randomised controlled trials of adults with type 2 diabetes comparing any dose and preparation of oral metformin with no intervention, placebo or a lifestyle intervention and reporting mortality or a cardiovascular outcome. RESULTS: We included ten articles reporting 13 trials (including a total of 2079 individuals with type 2 diabetes allocated to metformin and a similar number to comparison groups) of which only four compared metformin with placebo and collected data on cardiovascular outcomes. Participants were mainly white, aged ≤65 years, overweight/obese and with poor glycaemic control. Summary estimates were based on a small number of events: 416 myocardial infarctions/ischaemic heart disease events in seven studies and 111 strokes in four studies. The UK Prospective Diabetes Study (UKPDS) contributed the majority of data to the summary estimates, with weights ranging from 52.3% for myocardial infarction to 70.5% for stroke. All outcomes, with the exception of stroke, favoured metformin, with limited heterogeneity between studies, but none achieved statistical significance. Effect sizes (Mantel-Haenszel RR) were: all-cause mortality 0.96 (95% CI 0.84, 1.09); cardiovascular death 0.97 (95% CI 0.80, 1.16); myocardial infarction 0.89 (95% CI 0.75, 1.06); stroke 1.04 (95% CI 0.73, 1.48); and peripheral vascular disease 0.81 (95% CI 0.50, 1.31). CONCLUSIONS/INTERPRETATION: There remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in trials of metformin and a cardiovascular endpoint trial of metformin among people without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram [40]](https://figures.cochat.ai/paper-figures/21d83ef63bbb4a5890ce9f40e21450f3/impact-of-metformin-on-cardiovascular-disease-a-meta-analysis-of-randomised-figure-1.jpg)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In meta-analyses of 13 randomized clinical trials evaluating the CV effects of metformin vs. placebo or active control, including the data from the UKPDS, none of the differences in assessed CV outcomes was statistically significant.184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Excepting glimepiride, which was assessed for CV safety and efficacy head-to-head against linagliptin in the CAROLINA trial, and gliclazidemodified release, which was compared with usual care (that could have included treatment with a sulphonylurea other than gliclazide) in the ADVANCE trial, dedicated CV safety assessments have not been conducted for the other sulphonylureas.132,173,174,184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“12 weeks of treatment with licogliflozin led to a numerically greater reduction in liver lipid content, body weight (4.2 %) and HbA1c (1 %) compared to RCTs with sole SGLT2I treatment (Table 1) [161,163].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [163]
Experimental — accuracy not yet measuredIn the citing paper
“This Class IIa recommendation for metformin is based on the weight of opinion rather than the weight of evidence; results from meta-analyses of observational studies suggest associations with better CV outcome, but this is not supported by results from meta-analyses restricted to randomized trials in patients with T2DM and ASCVD, where no statistically significant effect of metformin has been”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
In the citing paper
“The pooled HRs (95% CIs) were: all-cause mortality 0.96 (0.84-1.09);CV death 0.97 ( 0.80-1.16); MI 0.89 (0.75-1.06); stroke 1.04 (0.73-1.48); and peripheral vascular disease 0.81 (0.50-1 31).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 308
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Metformin reduced the incidence of diabetes by 31% among people with glucose levels just below the diagnostic threshold in the US Diabetes Prevention Programme [36], and by 26% in the Indian equivalent [37].”
BackgroundEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 10×
“studies [19, 21] to 15 years [27]) and poorly controlled diabetes (average baseline HbA1c was less than 8% [63.”
BackgroundMethodInfluentialLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“This contrasts with the evidence now available for newer and more expensive glucose-lowering drugs, such as empagliflozin [34] and liraglutide [10], and of course for medications targeting different risk factors, for example statins.”
Background
Cited by
Items 101–200 of 398
Zheng, J., Xu, M., Yang, Q., Hu, C., Walker, V. M., Lu, J., Wang, J., Liu, R., Xu, Y., Wang, T., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104803 · Cited by 39
Sim, R., Chong, C. W., Loganadan, N. K., Fong, A. Y. Y., Navaravong, L., Hussein, Z. B., Khunti, K., & Lee, S. W. H. (2022) · Diabetic Medicine · doi:10.1111/dme.14780 · Cited by 39
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
Li, H., Tse, Y.-K., Chandramouli, C., Hon, N. W. L., Cheung, C., Lam, L.-Y., Wu, M., Huang, J.-Y., Yu, S.-Y., Leung, K. L. C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac558 · Cited by 36
Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin
Chan, J. C. N., Yang, A., Chu, N. H. S., & Chow, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15700 · Cited by 38
“66,67 In a meta-analysis of RCTs including 2079 patients with T2D, 66 with non-use of metformin.”
Targosz‐Korecka, M., Malek-Zietek, K. E., Klóska, D., Rajfur, Z., Stępień, E. Ł., Grochot‐Przeczek, A., & Szymoński, M. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129533 · Cited by 34
He, X., Wu, D., Hu, C., Xu, T., Liu, Y., Liu, C., Xu, B., & Tang, W. (2018) · Thyroid · doi:10.1089/thy.2017.0707 · Cited by 38
Yoo, S. G., Han, K. D., Lee, K. H., La, Y., Kwon, D. E., & Han, S. H. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0167 · Cited by 32
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
NAFLD in type 2 diabetes mellitus: Still many challenging questions
Cernea, S., & Raz, I. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3386 · Cited by 39
“There is uncertainty regarding metformin's potential to decrease CVD, but metaanalysis of RCTs has proven its CV safety.(125)”
BackgroundThe Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy
Gopal, K., Chahade, J. J., Kim, R., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.603247 · Cited by 38
“either no intervention, placebo, or lifestyle intervention), but none of these observations reached statistical significance (Griffin et al., 2017).”
BackgroundMetformin ameliorates acetaminophen-induced sub-acute toxicity via antioxidant property
Tripathi, S. S., Singh, S., Garg, G., Kumar, R., Verma, A. K., Singh, A. K., Bissoyi, A., & Rizvi, S. I. (2019) · Drug and Chemical Toxicology · doi:10.1080/01480545.2019.1658769 · Cited by 34
“At present, metformin has been scrutinized by several investigators for desirable protection in several disease models such as aging, cardiovascular diseases, neurodegenerative diseases and cancer (Barzilai et al. 2016, Griffin et al. 2017, Markowicz-Piasecka et al. 2017, Zi et al. 2018).”
BackgroundChiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 31
“31,32 In the UKPDS trial, only 1.5% patients received aspirin, and less than 1% received statins.”
InfluentialIonică, L. N., Gaiţă, L., Bînă, A. M., Șoșdean, R., Lighezan, R., Sima, A. C., Malita, D. C., Cretu, O. M., Burlacu, O. N., Muntean, D. M., et al. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04194-2 · Cited by 31
Chow, E., Yang, A., Chung, C. H. L., & Chan, J. C. N. (2022) · Pharmaceuticals · doi:10.3390/ph15040442 · Cited by 35
“In a meta-analysis of RCTs including 2079 patients with T2D [40], metformin use was associated with reduced risk of cardiovascular death, myocardial infarction, and peripheral vascular disease compared with non-use of metformin.”
BackgroundDu, Y., Zhu, J., Guo, Z., Wang, Z., Wang, Y., Hu, M., Zhang, L., Yang, Y., Wang, J., Huang, Y., et al. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2306223 · Cited by 33
Ram, E., Lavee, J., Tenenbaum, A., Klempfner, R., Fisman, E. Z., Maor, E., Ovdat, T., Amunts, S., Sternik, L., & Peled, Y. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0925-y · Cited by 30
Tsapas, A., Karagiannis, T., Avgerinos, I., Liakos, A., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108921 · Cited by 29
Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering
Neuen, B. L., Cherney, D. Z. I., Jardine, M., & Perkovic, V. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190047 · Cited by 32
Escobar, C., Barrios, V., Cosín, J., Martínez, J. M. G., Rodrigo, A. I. H., Cortés, C. O., Llergo, J. T., Requeijo, C., Solà, I., & Martínez‐Zapata, M. J. (2021) · Diabetic Medicine · doi:10.1111/dme.14502 · Cited by 31
Hierons, S. J., Marsh, J. S., Wu, D., Blindauer, C. A., & Stewart, A. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810140 · Cited by 30
“Interestingly, the ability of metformin to confer true cardiovascular benefit has come into question in recent years [140,141].”
BackgroundGlycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues
Longo, M., Scappaticcio, L., Cirillo, P., Maio, A., Carotenuto, R. M., Maiorino, M. I., Bellastella, G., & Esposito, K. (2022) · Biomolecules · doi:10.3390/biom12020272 · Cited by 34
“079 individuals with DMT2 demonstrated that the use of metformin slightly improved the risk of all-cause mortality, cardiovascular death, myocardial infarction, and peripheral disease as compared with control strategies (no intervention, placebo, or lifestyle changes), but none of these outcomes achieved statistical s…”
BackgroundСалухов, В. В., Khalimov, Y. S., Борисович, Ш. С., & Kadin, D. V. (2018) · Diabetes Mellitus · doi:10.14341/dm9570 · Cited by 36
Exercise-Pharmacology Interactions: Metformin, Statins, and Healthspan
Miller, B. F., & Thyfault, J. P. (2020) · Physiology · doi:10.1152/physiol.00013.2020 · Cited by 33
Ferrannini, G., Gerstein, H., Colhoun, H. M., Dagenais, G. R., Diaz, R., Dyal, L., Lakshmanan, M., Mellbin, L., Probstfield, J., Riddle, M. C., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa777 · Cited by 28
Jacob, S., Krentz, A. J., Deanfield, J. E., & Rydén, L. (2021) · Drugs · doi:10.1007/s40265-021-01554-6 · Cited by 34
“Post-UKPDS trials led to an appreciation of the importance of lowering low-density lipoprotein (LDL) cholesterol using statins in patients with diabetes either as a secondary prevention measure [22] or in pursuit of primary prevention of cardiovascular disease in patients with type 2 diabetes [23].”
BackgroundInfluentialMetformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome
Jahn, L. A., Hartline, L. M., Liu, Z., & Barrett, E. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00287.2021 · Cited by 29
Jong, C.-B., Chen, K., Hsieh, M., Su, F., Wu, C., Voon, W., Hsieh, C., Shyu, K., Chong, J., Lin, W., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.03.021 · Cited by 27
Cordero‐Herrera, I., Guimarães, D. D., Moretti, C. H., Zhuge, Z., Han, H., Haworth, S. M., Gonzalez, A. E. U., Andersson, D. C., Weitzberg, E., Lundberg, J. O., et al. (2020) · Nitric Oxide · doi:10.1016/j.niox.2020.01.013 · Cited by 30
Polycystic Ovarian Syndrome: a Risk Factor for Cardiovascular Disease
Alvarez, Y. R., Pico, M. G., Ashokprabhu, N. D., Abou-Amro, K., Bailey, S., Pung, E., Oberholster, E., & Quesada, O. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01168-1 · Cited by 27
“Studies to date on the effects of metformin in reducing CVD mortality on cardiovascular disease are conflicting [78, 79].”
Cardiovascular Risks and Benefits of Medications Used for Weight Loss
Bramante, C. T., Raatz, S. J., Bomberg, E. M., Bensignor, M. O., & Ryder, J. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00883 · Cited by 27
“Other meta-analyses have not concluded there are statistically significant CV benefits of metformin on allcause mortality, CVmortality, MI, peripheral vascular disease, or stroke (38, 39).”
BackgroundNeuen, B. L., Jardine, M., & Perkovic, V. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz252 · Cited by 28
Dihoum, A., Rena, G., Pearson, E. R., Lang, C. C., & Mordi, I. R. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2196010 · Cited by 33
Safety and effectiveness of metformin in patients with reduced renal function: a systematic review
Orloff, J., Min, J. Y., Mushlin, A., & Flory, J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14440 · Cited by 24
The use of geroprotectors to prevent multimorbidity: Opportunities and challenges
Morsli, S., & Bellantuono, I. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111391 · Cited by 28
Fralick, M., Schneeweiß, S., Redelmeier, D. A., Razak, F. A., Gomes, T., & Patorno, E. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14474 · Cited by 24
Kheniser, K. G., Kashyap, S. R., & Kasumov, T. (2018) · Obesity Science & Practice · doi:10.1002/osp4.309 · Cited by 24
“There have been trials that suggest metformin does indeed reduce cardiovascular disease risk (61), but it remains an ongoing debate (62).”
Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., et al. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115964 · Cited by 24
Hu, D., Li, Z., Zhu, Y.-T., & Li, C. (2020) · Aging · doi:10.18632/aging.202392 · Cited by 27
Advances in metformin‐delivery systems for diabetes and obesity management
Abbasi, M., Heath, B., & McGinness, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15759 · Cited by 28
“32,33 Metformin exerts its beneficial effects through various signalling pathways.”
Prototypes of User Interfaces for Mobile Applications for Patients with Diabetes
Pavlas, J., Krejcar, O., Marešová, P., & Selamat, A. (2018) · Computers · doi:10.3390/computers8010001 · Cited by 23
“Relevant literature sources [12,13], which reveals that though mobile applications are generally beneficial in the treatment of diabetes mellitus [3], their functionality is insufficient, and applications do not make use of their full potential [14].”
BackgroundJi, L., Chan, J. C. N., Yu, M., Yoon, K., Kim, S. G., Choi, S. H., Huang, C., Tu, S., Wang, C., Paldánius, P. M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14205 · Cited by 28
Ciofani, J. L., Han, D., Allahwala, U. K., Woolf, B. A. R., Gill, D., & Bhindi, R. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.08.007 · Cited by 24
Cellular Protein Quality Control in Diabetic Cardiomyopathy: From Bench to Bedside
Kaur, N., Raja, R., Ruiz‐Velasco, A., & Liu, W. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.585309 · Cited by 24
Yang, W., Yang, Y., Wang, Y., Gao, Z., Zhang, J., Gao, W., Chen, Y., Lü, Y., Wang, H., Zhou, L., et al. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5395 · Cited by 23
“Metformin is efficient at alleviating a wide range of conditions, such as obesity (17), eating disorders (18), tumours (19), cardiovascular disease (20,21), polycystic ovary syndrome (22), kidney disease (23), cell senescence (24), osteoporosis (OP) (25) and osteoarthritis (OA) (26).”
BackgroundEmerging uncertainty on the anti-aging potential of metformin
Keys, M. T., Hallas, J., Miller, R. A., Suissa, S., & Christensen, K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102817 · Cited by 29
“More recent meta-analyses of clinical trials of glucose-lowering medications have suggested that metformin may be neutral with respect to most cardiovascular event outcomes and mortality (Palmer et al., 2016; Zhu et al., 2020; Tsapas et al., 2020; Griffin et al., 2017).”
Sundström, J., Kristófi, R., Östlund, O., Bennet, L., Eliasson, B., Jansson, S. P. O., Leksell, J. K., Almby, K. E., Lundqvist, M., & Eriksson, J. W. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107996 · Cited by 23
“…reviews of the totality of the evidence have not conclusively shown protective effects of metformin on clinically important outcomes when compared to diet or placebo 9,10 or other classes of GLDs. 11 16 However, their effects on clinical outcomes at earlier stages of diabetes is still unknown.”
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1193-3793 · Cited by 33
Repurposing Metformin for Vascular Disease
Triggle, C. R., Marei, I., Ye, K., Ding, H., Anderson, T. J., Hollenberg, M. D., & Hill, M. A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220729154615 · Cited by 26
Liu, J., Zhang, M., Deng, D., & Zhu, X. M. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01445-2 · Cited by 25
Bahardoust, M., Mousavi, S., Yariali, M., Haghmoradi, M., Hadaegh, F., Khalili, D., & Delpisheh, A. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01309-y · Cited by 21
Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., Ishii, H., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0865 · Cited by 26
“However, no significant difference in risk reduction was observed between the metformin and placebo groups [199].”
BackgroundChallenging 2019 ESC guidelines for the management of type 2 diabetes
Scheen, A. J. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.10.006 · Cited by 20
Kim, Y.-S., Choi, E.-A., Lee, J., Kim, Y., You, H., Han, Y.-E., Kim, H.-S., Bae, Y., Kang, H., & Kim, J. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.010 · Cited by 19
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 23
“However, a meta-analysis of clinical trials published in 2017 did not show a reduction in CV events or mortality with metformin [48].”
BackgroundMethodMetformin protects red blood cells against rotenone induced oxidative stress and cytotoxicity
Tripathi, S. S., Singh, A. K., Akhtar, F., Chaudhary, A., & Rizvi, S. I. (2019) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2019.1620288 · Cited by 18
Sciannimanico, S. M., Grimaldi, F., Vescini, F., Pergola, G. D., Iacoviello, M., Licchelli, B., Guastamacchia, E., Giagulli, V. A., & Triggiani, V. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190507125847 · Cited by 22
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 20
“A recent meta-analysis of 13 studies of metformin in T2D concluded that metformin appeared to be safe, but no significant reduction in cardiovascular risk could be concluded [11].”
BackgroundTreating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs
Lunder, M., Janić, M., & Šabović, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062796 · Cited by 20
“Another meta-analysis showed that metformin acted favorably on all-cause mortality, cardiovascular death, and myocardial infarction, the differences not being statistically significant [51].”
BackgroundJang, D. K., Choi, J. H., Paik, W. H., Ryu, J. K., Kim, Y.-T., Han, K.-D., & Lee, S. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-21852-7 · Cited by 18
Paridari, P., Jabermoradi, S., Gholamzadeh, R., Vazifekhah, S., Vazirizadeh-Mahabadi, M., Dizaji, S. R., Forouzannia, S. A., Hosseini, M., & Yousefifard, M. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102721 · Cited by 23
SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials
Jia, X., Mehta, P. B., Ye, Y., Alam, M., Birnbaum, Y., & Bajaj, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1038-9 · Cited by 19
Katsiki, N., Ferrannini, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154218 · Cited by 20
Lee, H. W., Lee, J. S., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., & Kim, S. U. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107747 · Cited by 21
Translating the dose response into risk and benefit
Warren, J. B. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13949 · Cited by 22
Tu, W., Liu, Z., Chao, B., Yan, F., Ma, L., Cao, L., Ji, X., & Wang, L. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221076894 · Cited by 20
Muzurović, E. M., & Mikhailidis, D. P. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420941675 · Cited by 17
the directors of the JCS, J., Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00471-5 · Cited by 17
Tao, L., Fan, X., Sun, J., & Zhang, Z. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.119015 · Cited by 18
Similarities and Distinctions in the Effects of Metformin and Carbon Monoxide in Immunometabolism.
Park, J., Joe, Y., Ryter, S. W., Surh, Y., & Chung, H. (2019) · PubMed Central · doi:10.14348/molcells.2019.0016 · Cited by 19
“…has been used to treat not only DM2 but also other metabolic diseases, such as CVD, non-alcoholic fatty liver disease (NAFLD) and cancer, in both an AMPKdependent and -independent manner (Ben Sahra et al., 2011; Gotlieb et al., 2008; Griffin et al., 2017; Kim et al., 2013a; Zakikhani et al., 2006).”
BackgroundAssociation of Metformin and Abdominal Aortic Aneurysm Repair Outcomes
Turowicz, A., Kobecki, J., Laskowska, A., Wojciechowski, J., Świątkowski, F., & Chabowski, M. (2021) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2021.02.048 · Cited by 18
Sattar, N. A., & McGuire, D. K. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa879 · Cited by 18
He, X., Wang, L., Chen, X., Liang, Q., Wang, W., Lin, A., Yi, L., Wang, Y., & Gao, Q. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000333 · Cited by 16
Bethel, M. A., Stevens, S. R., Buse, J. B., Choi, J., Gustavson, S. M., Iqbal, N., Lokhnygina, Y. V., Mentz, R. J., Patel, R. A., Öhman, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043353 · Cited by 17
Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease
Escott, G. M., da Silveira, L. G., Cancelier, V. D. A., Dall’Agnol, A., & Silveiro, S. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107774 · Cited by 17
Sawami, K., Tanaka, A., & Node, K. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01611-8 · Cited by 15
Wilmanns, J. C., Pandey, R., Hon, O. J., Chandran, A., Schilling, J. M., Forte, E., Wu, Q., Cagnone, G., Bais, P., Philip, V. M., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.11.002 · Cited by 15
Metformin: still the sweet spot for CV protection in diabetes?
Rena, G., Mordi, I. R., & Lang, C. C. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.018 · Cited by 16
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Martínez, J. J. G. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.03.005 · Cited by 19
Yang, Q., Wang, G., Fang, D., Gao, X., Yu, L., Wang, L., Wu, J., Zeng, M., & Luo, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113130 · Cited by 14
Xu, Z., Zhang, H., Wu, C., Zheng, Y., & Jiang, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.944902 · Cited by 16
“A meta-analysis of 13 randomized trials showed that metformin couldn’t remarkably reduce AMI and stroke (86), so there remains uncertainty about whether metformin reduces the risk of MACEs, AMI, stroke, and heart failure in patients with T2DM or not, and our included studies were limited (3 AMI studies, 3 stroke studi…”
BackgroundAcid-base and electrolyte disturbances in patients with diabetes mellitus
Pipeleers, L., Wissing, K. M., & Hilbrands, R. (2018) · Acta Clinica Belgica · doi:10.1080/17843286.2018.1546983 · Cited by 15
“in type 2 diabetes patients [10], but this effect has not been confirmed in a meta-analysis [11].”
BackgroundPalui, R., Sahoo, J., Kamalanathan, S., Kar, S. S., Sridharan, K., Durgia, H., Raj, H., & Patil, M. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01059-w · Cited by 19
Mansouri, F., & Seyed-Mohammadzad, M. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102602 · Cited by 14
Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
Andraos, J., Smith, S. R., Tran, A., & Pham, D. Q. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01406-6 · Cited by 20
Kazemi, A. H., Wang, W., Wang, Y., Khodaie, F., & Rezaeizadeh, H. (2019) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2019.02.003 · Cited by 21
Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin
Borg, M. J., Rayner, C. K., Jones, K. L., Horowitz, M., Xie, C., & Wu, T. (2020) · Pharmaceuticals · doi:10.3390/ph13110410 · Cited by 17
“These cardiovascular benefits were confirmed in a number of subsequent studies [6–9], although, in a minority of studies, neutral or deleterious cardiovascular outcomes were reported with metformin use in T2D [10,11].”
ResultThe SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Tilinca, M. C., Tiucă, R. A., Ţilea, I., & Varga, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121249 · Cited by 15
Analysing the impact of modifiable risk factors on cardiovascular disease mortality in Brazil
Gaspar, R. S., Rezende, L. F. M., & Laurindo, F. R. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269549 · Cited by 18
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Zhang, B., Cao, Y. Y., Qu, Z., Sun, Y., & Tian, X. (2024) · Endocrine · doi:10.1007/s12020-024-04012-x · Cited by 12
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus
Martínez, J. J. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030678 · Cited by 16
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 24
Amirsaadat, S., Hosseini, M. S., Amjadi, A., Sarvari, R., Mofrad, Y. M., & Zarghami, N. (2025) · Results in Engineering · doi:10.1016/j.rineng.2025.104817 · Cited by 12
Nyambuya, T. M., Dludla, P. V., & Nkambule, B. B. (2018) · Systematic Reviews · doi:10.1186/s13643-018-0835-1 · Cited by 14
Metformin Attenuates Early-Stage Atherosclerosis in Mildly Hyperglycemic Oikawa-Nagao Mice
Asai, A., Shuto, Y., Nagao, M., Kawahara, M., Miyazawa, T., Sugihara, H., & Oikawa, S. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48223 · Cited by 15
Álvarez, C. A., Halm, E. A., Pugh, M. J., McGuire, D. K., Hennessy, S., Miller, R. T., Lingvay, I., Vouri, S. M., Zullo, A. R., Yang, H., et al. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.170 · Cited by 15
Guarino, G., Corte, T. D., Strollo, F., & Gentile, S. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.03.032 · Cited by 19
Lu, K.-Y., Dass, K. T. P., Lin, S., Tseng, Y., Liu, S., & Harn, H. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159033 · Cited by 12
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Athyros, V. G., Doumas, M. N., & Karagiannis, A. I. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190426162746 · Cited by 13
Metadata
- Authors
- Griffin, S. J., Leaver, J. K., & Irving, G. J.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Griffin, Simon J.
- Venue
- Diabetologia
- Published
- 2017-08-02
- Volume
- 60
- Issue
- 9
- Pages
- 1620-1629
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC5552849
- OpenAlex
- W2740802742
- Cited by
- 398
- References
- 45
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 33 · 2023: 31 · 2022: 52 · 2021: 60 · 2020: 75 · 2019: 64 · 2018: 39 · 2017: 8
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Edge Hill University Research Information Repository (Edge Hill University) (publishedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- University of Cambridge
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, type 2 diabetes, cardiovascular disease, myocardial infarction, stroke, all-cause mortality, cardiovascular mortality, peripheral vascular disease, ischemic heart disease, UK Prospective Diabetes Study, lifestyle intervention, drug effectiveness, cardiovascular risk reduction, glycemic control, randomized controlled trials, meta-analysis of trials, study heterogeneity, publication bias
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.